TNBC response to CDK4/6 inhibitors plus RANKL inhibitors

ABSTRACT: CDK4/6i alone have proven to be largely ineffective in TNBC, even in the presence of functional retinoblastoma protein (pRB). In this study, we investigated the role of the RANK pathway in the response to CDK4/6i in pRB-proficient TNBC. Transcriptomic analysis of xenografts revealed that combining CDK4/6i with RANKLi more effectively arrested the cell cycle.

ORGANISM(S): Homo sapiens

PROVIDER: GSE277615 | GEO | 2025/05/20

REPOSITORIES: GEO